Article

Defining the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase Inhibitors

2021-07-18

Abstract excerpt

<h4>Background</h4> Tyrosine kinase inhibitors (TKIs) therapy is a standard treatment for patients with advanced non-small-cell lung carcinoma (NSCLC) when activating epidermal growth factor receptor ( EGFR ) mutations are detected. However, except for the well-studied EGFR mutations, most EGFR mutations lack treatment regimens. <h4>Methods</h4> We constructed two EGFR variant libraries containing substitut...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c7f52dab-ba9a-5e02-b18f-c0b9ec0060ea
DOI: 10.1101/2021.07.18.452818

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Defining the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase InhibitorsDOI 10.1101/2021.07.18.452818Read

Defining the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase InhibitorsSemantic proximity Read

Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors.Semantic proximity Read

Six first-line tyrosine kinase inhibitors reveal novel inhibition potential for the EGFR S768I mutation.Semantic proximity Read

Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants.Semantic proximity Read

Computational Analysis of Epidermal Growth Factor Receptor Mutations Predicts Differential Drug Sensitivity Profiles toward Kinase Inhibitors.Semantic proximity Read

Overcoming Resistance in EGFR-Mutant Cancers: A Comprehensive Review of Inhibitor Evolution and SAR-Based Design.Semantic proximity Read

TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR MutationsSemantic proximity Read

Deep Mutational Scanning Reveals EGFR Mutations Conferring Resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945Semantic proximity Read

Deep mutational scanning reveals EGFR mutations conferring resistance to the 4th-generation EGFR tyrosine kinase inhibitor BLU-945Semantic proximity Read

Saturation resistance profiling of EGFR variants against tyrosine kinase inhibitors using prime editingSemantic proximity Read

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase InhibitorsSemantic proximity Read

Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry).Semantic proximity Read